

June 11, 2018



Ensysce Biosciences to Participate in New Generation Analgesics Symposium at Annual Meeting of the College on Problems of Drug Dependence

SAN DIEGO--(BUSINESS WIRE)-- Ensysce Biosciences, Inc., an integrated drug delivery company for both small and large molecules, today announced that D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will be an invited speaker at the upcoming symposium titled New Generation Analgesics at the 80th Annual Meeting of the College on Problems of Drug Dependence (CPDD 2018). The meeting will be held June 9-14, 2018, at the Hilton San Diego Bay Front, San Diego, California. Dr. Kirkpatrick's talk will discuss the company's opioid prodrug and overdose protection technologies that can help to prevent the serious problems of drug abuse and overdose. Further information on details on CPDD 2018 can be found [here](#).

Research to be presented in this symposium will highlight advances from four different research groups in developing safer and/or less addictive opioid analgesics. The discussant, Nora D. Volkow, M.D., Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health, will put the presentations in context by highlighting the efforts of other research groups to develop non-opioid alternatives for analgesia, and will present a vision of NIH/NIDA support for future pain research. The overall goal of the symposium is to encourage future research on pain and the development of safer/less addictive analgesics by focusing the attention of meeting attendees on recent advances and gap areas of knowledge in this field of research.

About Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is an integrated drug delivery company for both small and large molecules. To overcome the major problem of non-medical use of opioid products, Ensysce is using its prodrug technology to improve abuse deterrent properties. The BIO-MD™ prodrug abuse deterrent and MPAR™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. This is the fastest growing drug problem in the U.S. and it leads to billions in healthcare costs annually. For additional information about Ensysce Biosciences please visit www.ensysce.com.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20180611005005/en/>

Ensysce Biosciences Inc.
D. Lynn Kirkpatrick, Ph.D., 858-242-1553
CEO

lkirkpatrick@ensysce.com

Source: Ensysce Biosciences, Inc.